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The developed standardized human cell based in vitro angiogenesis assay was intra-laboratory 
pre-validated to verify that the method is reliable and relevant for routine testing of modulators 
of angiogenesis, e.g., pharmaceuticals and industrial chemicals. This assay is based on the 
earlier published method but it was improved and shown to be more sensitive and rapid 
than the previous assay. The performance of the assay was assessed by using six reference 
chemicals, which are widely used pharmaceuticals that inhibit angiogenesis: acetyl salicylic 
acid, erlotinib, 2-methoxyestradiol, levamisole, thalidomide, and anti-vascular endothelial growth 
factor. In the intra-laboratory pre-validation, the sensitivity of the assay (upper and lower limits 
of detection and linearity of response in tubule formation), batch to batch variation in tubule 
formation between different Master cell bank batches, and precision as well as the reliability 
of the assay (reproducibility and repeatability) were tested. The pre-set acceptance criteria 
for the intra-laboratory pre-validation study were met. The relevance of the assay in man was 
investigated by comparing the effects of reference chemicals and their concentrations to the 
published human data. The comparison showed a good concordance, which indicates that this 
human cell based angiogenesis model predicts well the effects in man and has the potential 
to be used to supplement and/or replace of animal tests.
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angiogenesis (Auerbach et al., 2003; Norrby, 2006) or embryonic, 
and organogenic angiogenesis (Norrby, 2006). Despite the advantage 
of providing more information on complex cellular and molecular 
interactions compared to in vitro models (Norrby, 2006), animal 
models are burdened by several disadvantages such as variability, 
animal-specificity, and unethical procedures (Norrby, 2006; Ishikane 
et al., 2008). The current in vivo assays are not pertinent to human 
diseases as regards both efficacy and relevance (Norrby, 2006). 
Therefore, human cell based (in vitro) assays would have potential 
to be more predictive than animal models when investigating the 
effects in man.
Current in vitro angiogenesis assays include cell proliferation 
and cell migration assays, tubule formation assays, and organ 
culture assays (Auerbach et al., 2003; Ucuzian and Greisler, 2007). 
Three-dimensional in vitro assays permit cell-to-cell interactions, 
but responses are often difficult to evaluate and quantitate. Most 
cell culture assays (e.g., tubule formation assays in collagen or 
Matrigel, cell motility assays, trans-membrane assays, or cell 
proliferation assays) only reflect one single step of angiogenesis 
(Auerbach et al., 2003). An ideal in vitro assay would measure 
both stimulation and inhibition (Bishop et al., 1999; Norrby, 
2006) and provide quantitative measurement of the tubule for-
mation (Norrby, 2006). Although tubule formation in vitro does 
not cover the whole angiogenesis process, it effectively mimics 
the key steps, i.e., migration and differentiation of endothelial 
cells (Donovan et al., 2001).
IntroductIon
Angiogenesis, the formation of new blood vessels, is a multistep 
process regulated by an interplay of pro- and anti-angiogenic fac-
tors. The steps involved are: endothelial cell proliferation, migra-
tion, differentiation, and tubule formation, as well as stabilization 
of newly formed blood vessels by a layer of pericytes and smooth 
muscle cells (Beilmann et al., 2004; Folkman, 2006; Nillesen et al., 
2007). Angiogenesis is involved in critical physiological processes 
such as in embryonic development, wound healing, and female 
reproductive cycle (Friis et al., 2003; Berthod et al., 2006; Norrby, 
2006), as well as in pathologic processes such as in tumor develop-
ment and macular degeneration (Friis et al., 2003), rheumatoid 
arthritis (Friis et al., 2003; Middleton et al., 2004), ischemic diseases 
(van Weel et al., 2008; Cao, 2009), endometriosis (Rogers et al., 
2009), and psoriasis (Folkman, 2006).
Due to complex interactions during angiogenesis, the evalua-
tion of factors that affect angiogenesis would optimally be studied 
in vivo (Auerbach et al., 2003). The most commonly used in vivo 
angiogenesis assays include chick chorioallantoic membrane (CAM) 
assay, Matrigel plug assay, zebrafish embryo system, corneal micro-
pocket assay, rat/mouse hind limb ischemia model, rat aortic ring 
assay, intradermal angiogenesis assays, and Xenopus tadpole assay 
(Auerbach et al., 2003). These in vivo assays are used to measure 
new blood vessel formation by pro- and anti-angiogenic factors and 
compounds (Akhtar et al., 2002; Auerbach et al., 2003; Norrby, 2006; 
Ishikane et al., 2008; Ziche and Morbidelli, 2009), and to study tumor Frontiers in Pharmacology  | Predictive Toxicity    January 2011  | Volume 1  | Article 147  |  2
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The objective of the study was to intra-laboratory pre-validate 
the optimized test method for testing of angiogenesis modula-
tors in routine use to replace and/or supplement animal experi-
ments. The co-culture assay published by Bishop et al. (1999) 
and Donovan et al. (2001) was further developed, optimized and 
finally pre-  validated in the laboratory. All critical steps including 
cell isolation procedure, cell number, cell passage, culture time, and 
tubule formation procedure as well as microscopic analysis were 
thoroughly investigated and optimized before the intra-laboratory 
pre-validation. During the intra-laboratory pre-validation, the per-
formance of the assay was assessed by using six reference chemicals, 
inhibitors of angiogenesis, with animal and human data available; 
levamisole hydrochloride (levamisole), acetyl salicylic acid (ASA), 
thalidomide, erlotinib hydrochloride (erlotinib), anti-vascular 
endothelial growth factor (anti-VEGF), and 2-methoxyestradiol 
(2-ME). The relevance of the method to man was shown by com-
paring the obtained results to the literature data from the clinical 
studies with the same compounds. We here show that through 
thorough optimization and intra-laboratory pre-validation, it is 
possible to develop cell a culture assay into a reproducible and 
repeatable routine method with minimal variation and easy and 
fast semi-quantitative analysis of the effects.
MaterIals and Methods
MaterIals and cheMIcals
The BJ human foreskin fibroblasts were purchased from 
American Type Culture Collection (ATCC, LGC Promochem 
AB, Boras, Sweden, Cat. No. CRL-2522, Lot No. 57632920). 
Fetal bovine serum (FBS, Cat. No. 10106), l-glutamine (Glu, 
Cat. No. 25030), non-essential amino acids (NEAA, Cat. No. 
11140), and TrypLE Express (Cat. No. 12604) were obtained 
from Gibco, Invitrogen, Carlsbad, CA, USA. DAB Substrate Kit 
(Cat. No. 00-2014) was from Zymed Laboratories Inc, Invitrogen, 
Carlsbad, CA, USA. EGM-2 bullet kit including SingleQuots-
supplements (Cat. No. CC-3162), endothelial basal medium 
(EBM; Cat. No. CC-3156), EGM-2 SingleQuots-supplements 
(Cat. No. CC-4176), Gentamicin sulfate 50 mg/ml (Cat. No. 
17-518Z), and Amphotericin B 250 μg/ml (Cat. No. 17-836E) 
were obtained from Lonza Group Ltd., Basel, Switzerland. 
Recombinant Human Fibroblast Growth Factor-basic 146 AA 
(FGF-2, Cat. No. 233-FB, Lot. No. HKW3809032, ED50 for induc-
ing proliferation of NR6R-3T3 mouse fibroblasts is typically 0.1–
0.6 ng/ml) and Recombinant human vascular endothelial growth 
factor 165 (VEGF, Cat. No. 293-VE, Lot. No. II2209012, ED50 for 
inducing proliferation of human umbilical vein endothelial cells 
(HUVEC) is typically 2.0–6.0 ng/ml) were obtained from R&D 
Systems, Abingdon, UK. 1,4-Ditiotreitol (DTT, Cat. No. 233156, 
Molecular Biology Grade) was obtained from Calbiochem, San 
Diego, CA, USA. Bovine serum albumin fraction V (BSA, Cat. No. 
107350940019) was from Roche, Indianapolis, IN, USA. Erlotinib 
(Lot. No. BS06110030) was a kind gift from Roche Diagnostics 
GmbH, Mannheim, Germany. Anti-von Willebrand Factor (Anti-
vWf) antibody produced in rabbit (Cat. No. F-3520), Neutral 
Red (NR) Solution (Cat. No. N2889), anti-VEGF (Cat. No. 
V6627, Lot. No. 088K1260), thalidomide (Cat No. T144, Lot. 
No. 097K4601), levamisole (tetramisole hydrochloride, Cat. No. 
L9756, Lot. No. 088K0753), 2-ME (Cat. No. M6383, Lot. No. 
108K4087), and ASA (Cat. No. A5376, Lot. No. 048K0015) were 
from Sigma Aldrich, Manassas, VA, USA. Biotinylated anti-rabbit 
IgG (H + L) made in goat (Cat. No. BA-1000) and Vectastain Elite 
ABC Kit, Standard (Cat. No. PK-6100) were purchased from 
Vector laboratories Inc, Burlingame, CA, USA. Triton X-100 was 
from JT Baker, Phillipsburg, NJ, USA. Collagenase I was pur-
chased from Invitrogen, Paisley, Scotland, UK. A 75-cm2 filtered 
cell culture flasks (Nunc EasyFlask™) were from Nunc, Roskilde, 
Denmark. MycoAlert® Mycoplasma Detection Kit (LT07-118) was 
purchased from Lonza Group Ltd., Basel, Switzerland.
PosItIve and negatIve controls
The tubule formation potency of each reference chemical was 
quantified based on the tubule formation potency of the posi-
tive control. The negative control compound induced no tubule 
formation. The positive control was a cocktail of commercial, 
well known angiogenic factors, VEGF, and fibroblast growth 
factor 2 (FGFβ or FGF-2), that are widely used to mimic the 
human tubule formation in vitro (Bishop et al., 1999; Cross 
and Claesson-Welsh, 2001; Donovan et al., 2001; Friis et al., 
2003; Ai et al., 2007). The positive control medium consisted of 
10 ng/ml VEGF and 1 ng/ml FGF-2 dissolved in endothelial basal 
medium (EBM). The optimal positive control was chosen by 
testing   different concentrations of VEGF and FGF-2 (Table 1). 
As the negative control compound, which induced no tubule for-
mation, endothelial basal medium (EBM) without any growth 
factors was used. Negative control gave the same response as 
the solvent. Positive control was used in four parallels and 
negative control in two parallels throughout the procedure in 
each 48-well plate to ensure the technical validity of the tests. 
Additionally, the dimethyl sulfoxide (DMSO) control was used 
in three of the reference chemicals (thalidomide, erlotinib, and 
2-ME) as they were dissolved in DMSO. DMSO concentration 
never exceeded 0.5%.
reference cheMIcals
The six reference chemicals and their concentrations used for 
pre-validation of an in vitro angiogenesis assay are shown in Table 2. 
The rationale behind selection of the reference chemicals were 
that they are consistent with the defined objectives of the study 
(known inhibitors of angiogenesis), they represent different types 
Table 1 | The growth factor cocktails used in investigation of the optimal 
positive control, linearity, upper and lower limits and batch to batch 
variation.
Growth factor cocktail no.  VEGF/FGF-2  
  concentration (ng/ml)
1  75/7 .5
2  50/5.0
3  25/2.5
4  10/1.0
5  7 .5/0.75
6  5.0/0.5
7  2.5/.25
8  1.0/0.1www.frontiersin.org  January 2011  | Volume 1  | Article 147  |  3
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Methods
Setting up Master cell banks
Quality control (QC) criteria for setting up Master cell banks were 
as follows: cell cultures were pure with high proliferation capacity 
and contained no mycoplasma. Cell viability was over 90%. Cell 
culture was quality-controlled microscopically and always prior 
to Master cell bank establishment. The cells were tested for myco-
plasma contamination with MycoAlert® Mycoplasma Detection Kit 
according to manufacturer’s instructions. The cell lines (human 
foreskin fibroblasts) were not passaged over 10 times and the pas-
saging of primary cells (HUVEC) was investigated and optimized. 
No antibiotics were used in cell culture.
Human foreskin fibroblasts. Human foreskin fibroblasts were 
obtained from ATCC and cultured in Minimum Essential Medium 
with Earle’s salts, w/o l-Glutamine supplemented with 10% FBS, 
1% l-glutamine, 1% NEAA, and 1% antibiotic–antimycotic mix-
ture in 75 cm2 cell culture flasks in 10 ml of medium at 37°C in 5% 
CO2 incubator. The medium was changed and the cells observed 
microscopically for their morphology and cell proliferation every 
3 days. When confluent, the cells were detached with Tryple Express 
and subcultured in a ratio of 1:9. The cells were cryopreserved in liq-
uid nitrogen, 500 000 cells per vial to create the Master cell bank.
Human umbilical vein endothelial cells. The human umbili-
cal cords were obtained from scheduled cesarean sections with 
informed consent from Tampere University Hospital (permis-
sion No. R08028 from the Ethics Committee of the Pirkanmaa 
Hospital District, Tampere, Finland). The isolation of umbilical 
vein endothelial cells (HUVEC) from human umbilical cord veins 
was performed as described by Jaffe et al. (1973) but the process 
was further optimized. The umbilical cord was separated from the 
placenta and the umbilical vein was cannulated with a 20G   needle. 
The needle was secured by clamping the cord over the needle with 
of   chemicals and reliable and relevant reference data in animals 
and man is available. No other inducers of angiogenesis than the 
positive control were included. The concentration range for each 
chemical was selected prior to the angiogenesis assay. The criteria 
for the selection of the chemical were non-toxicity, solubility in 
the test system, and that DMSO concentration not exceeding 0.5% 
in the test system. Reference chemicals were dissolved according 
to manufacturer’s instructions and further diluted in stimulation 
medium (=endothelial basal medium supplemented with 10 ng/ml 
VEGF and 1 ng/ml FGF-2) prior to use.
These reference chemicals are widely studied angiogenesis 
inhibitors and pharmaceuticals. Anti-VEGF is the first angio-
genesis inhibitor that has been approved by the U.S. Food and 
Drug Administration under trade name Avastin (bevacizumab) 
for the treatment of colon cancer (Folkman, 2006). According 
to Folkman (2006) VEGF antibody (trade name Lucentis) and 
aptamer of VEGF (trade name Macugen) are used for the treat-
ment of macular degeneration; erlotinib (trade name Tarceva), an 
epidermal growth factor receptor (EGFR) tyrose kinase inhibitor 
is used for the treatment of lung cancer; thalidomide is used for 
the treatment of multiple myeloma. ASA has protective effects 
against colon cancer and cardiovascular disease (Yan et al., 2010). 
2-ME is approved by FDA for the treatment of ovarian cancer 
under trade name Panzem. 2-ME has also been studied in the 
treatment of rheumatoid arthritis (Brahn et al., 2008), cardio-
vascular diseases (Dubey and Jackson, 2009), multiple myeloma 
(Rajkumar et al., 2007), breast cancer (Greenberg and Rugo, 
2010), and prostate cancer (Harrison et al., 2010). Levamisole 
(trade name Ergamisol) has been used to treat worm infesta-
tions in both humans and animals and it is tested in clinical trials 
for the treatment of chronic idiopathic urticaria (Zhang et al., 
2009), for colorectal cancer (Quasar Collaborative et al., 2007; 
Dahl et al., 2009), for malignant melanoma (Verma et al., 2006), 
and for malaria (Dondorp et al., 2007).
Table 2 | Reference chemicals tested in the intra-laboratory pre-validation of an in vitro angiogenesis assay.
Chemical name  CAS-RN  Chemical class  Product class  Concentrations tested  Purity  Supplier  Physical and 
             chemical 
             characteristics
Acetyl  50-78-2  Salicylate  Non-steroidal anti-  10, 100, 500, 1000,    99.9%  Sigma Aldrich  Powder 
salicylic acid     inflammatory  1500, and 2000 μM 
      drug (NSAID)
Erlotinib  183319-  Quinazoline  HER1/EGFR tyrosine   0.0005, 0.001, 0.01, 0.1,   99.9%  Roche  Powder 
  69-9   kinase inhibitor  1, 10, 25, and 50 μM   Diagnostics
Levamisole  16595-80-5  Imidazothiazole  Alkaline phosphatase  0.01, 0.1, 1, 10, 50,   99%  Sigma Aldrich  Powder 
      inhibitor  100, 250, 500, 750, 
        1000, and 2000 μM 
2-Methoxyestradiol  363-07-2  Estradiol metabolite  Tubulin inhibitor  0.01, 0.1, 0.2, 0.4, 0.6  99.5%  Sigma Aldrich  Powder 
        0.8, 1, and 2 μM
Thalidomide  50-35-1  Phthalimide  Immunomodulator,   10, 100, 200, 300, 400,  >99%  Sigma Aldrich  Powder 
      TNF-α inhibitor  and 500 μM
Anti-VEGF  n/a  Human VEGF165   Growth factor antibody  0.5, 1, 2.5, 5, 7 .5, 10, 25,   n/a  Sigma Aldrich  Lyophilized 
    and VEGF121   and 50 μg/ml     powder 
    antibody, IgG fraction         
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Angiogenesis assay
The angiogenesis assay was performed independently by two tech-
nicians and two analysts. The technicians performed the whole 
assay independently, except that the microscopic analysis was per-
formed independently and blinded by two analysts. For microscopic 
analysis the samples were coded by a person not directly involved 
in the study.
The co-culture of fibroblasts and HUVEC was first established 
as described above (see Co-Culture Establishment). The day after 
co-culture creation, the co-culture was exposed to the positive or 
negative controls (see Positive and Negative Controls), the refer-
ence chemical treatments (see Table 1) or growth factor cocktails 
(see Table 2). The cells were cultured at 37°C for 6 days prior 
to immunocytochemical staining. The media containing either 
reference chemicals, or growth factor cocktail, or positive control 
or negative control, were changed once during the assay, on the 
third day.
Immunocytochemical staining. At day 6 from the onset of the 
experiment, the tubules were immunostained with anti-vWF. 
The media were removed and the cells were washed three times 
with PBS, fixed with ice-cold 70% ethanol for 20 min, permeabi-
lized with 0.5% Triton X-100 (JT Baker, Phillipsburg, NJ, USA) 
for 15 min and blocked for unspecific staining with 10% BSA 
(Roche Diagnostics Corporation, Indianapolis, IN, USA) for 
30 min. After blocking, the cells were incubated with primary 
antibody (anti-vWf, 1:5000) at 4°C overnight or for 1–2 h in 
room temperature (RT). Cells were then washed three times 
with PBS, incubated for 30 min with the secondary antibody 
(biotinylated anti-rabbit IgG, H + L made in goat) and washed 
again three times with PBS. The cells were then incubated with 
enzyme conjugate solution (Vectastain Elite ABC Kit) for 30 min, 
after which substrate was added (DAB Substrate Kit). The color 
development was followed under microscope for 5–10 min and 
the reaction was stopped with 0.5 M Tris buffer. After staining, 
500 μl of Tris buffer was pipetted into each cell culture well 
and the plates were sealed with parafilm for storage at 4°C until 
microscopic analysis.
Microscopic analysis. After immunocytochemical staining, the 
tubules were analyzed with Nikon Eclipse TS100 microscope 
(Nikon, Tokyo, Japan). The extent of tubules and their branch-
ing was quantified using predetermined visually inspected semi-
quantitative grading scale from 0 to 8. The analysis and grading 
required expertise and therefore were performed by scientists. As 
the microscopic analysis was based on semi-quantitative visual 
analysis, we especially wanted to test the repeatability of the analysis. 
Therefore all plates and wells were coded and analyzed individually 
by two scientists. Figure 1 shows the tubule network formation 
from negative and positive control.
Statistics.  One-way analysis of variance with Dunnett’s post 
test was used for the statistical analysis of the reference chemi-
cal results. The linearity of tubule formation was tested with 
  linear regression and precision with coefficient of variation (CV). 
The day to day variation of technicians was tested with one-way 
analysis of variance, person to person variation between techni-
cians with unpaired t-test and person to person variation between 
a surgical clamp. The vein was perfused with Umbilical cord buffer 
solution (UBS; 0.1 M phosphate buffer solution containing 0.14 M 
NaCl, 0.004 M KCl, and 0.011 M glucose) to wash out blood after 
which the other end of the umbilical vein was clamped with a 
surgical clamp. The vein was infused with 0.05% collagenase I. 
The umbilical cord was incubated in a water bath at 37°C for up 
to 20 min. After incubation, the collagenase solution containing 
HUVEC was flushed from the cord by infusing the vein with UBS. 
The suspension was flushed out into a 50-ml polypropylene tube. 
The cells were centrifuged at 250×g for 10 min, resuspended in 
EGM-2 BulletKit medium, seeded into 75 cm
2 filtered cell culture 
flasks, and cultured at 37°C in 5% CO2 incubator.
The isolated HUVEC were daily observed microscopically for 
their morphology, cell culture purity, and cell proliferation. The 
medium was changed every 2–3 days. When confluent, the cells 
were detached with Tryple Express. Pure HUVEC cultures with 
good proliferation capacity were subcultured at primary culture 
(p0) in the ratio of 1:2–1:4 and at passages 1 (p1) upward in a ratio 
of 1:3–1:5. The isolated HUVEC were tested for their tubule forma-
tion capacity in the angiogenesis assay up to passage 10. At passage 
2 (p2), the cells were cryopreserved in liquid nitrogen, 500 000 cells 
per vial to create the Master cell bank. The donor-specific batch 
number was given to each batch stored in the Master cell bank.
Co-culture establishment
BJ fibroblasts were taken from the Master cell bank, thawed, and 
cultured as above (see Human Foreskin Fibroblasts) for 3 days. On 
day 3, the BJ fibroblasts were plated into 48-well plates at a cell den-
sity of 20 000 cells/cm2, and grown for an additional 3 days. On day 
3, the HUVEC were taken from the Master cell bank, thawed, and 
cultured as above (see Human Umbilical Vein Endothelial Cells), 
separately from BJ fibroblasts, for 3 days. On day 6, the HUVEC 
cells were carefully seeded on the top of BJ fibroblasts into 48-well 
plates at a cell density of 4000 cells/cm2. The co-culture was then 
further used for cytotoxicity test and for angiogenesis assay.
Cytotoxicity test
To find out the highest concentration for each reference chemi-
cal for the angiogenesis assay, a cytotoxicity test was performed. 
Both technicians performed individually the cytotoxicity test for 
each reference chemical. As the cytotoxicity assay, the neutral red 
uptake (NRU) cell viability assay was used. The co-culture of 
fibroblasts and HUVEC was first established as described above 
(see Co-Culture Establishment). Twenty-four hours after co-culture 
establishment, the test system was treated by exposing with positive 
or negative controls (see Positive and Negative Controls), or refer-
ence chemicals (see Reference Chemicals and Table 1) for 24 h. After 
exposure for 24 h, the exposure medium was removed and the cells 
were washed with preheated PBS. Two hundred fifty microliters of 
NR-medium (25 mg NR/1 ml medium) was added into the wells 
and incubated for 2 h at 37°C. After incubation, NR-medium was 
removed and the cells were washed with 250 μl PBS. After that, 
100 μl NR-desorption medium (50% EtOH, 1% acetic acid in H2O) 
was added into the wells and incubated in a shaker for 20 min, 
protected from light. After shaking, the cells were allowed to settle 
down for 5 min. The absorbance was measured at 540 nm with 
Thermo Scientific Varioskan Flash Spectral Scanning Multimode 
Reader (Thermo Fisher Scientific Inc., Waltham, MA, USA).www.frontiersin.org  January 2011  | Volume 1  | Article 147  |  5
Sarkanen et al.  The pre-validated in vitro angiogenesis assay
up in our laboratory gives comparable results. The batch to batch 
variation testing was performed in the angiogenesis assay with the 
growth factor cocktails shown in Table 1. Three HUVEC batches 
of passage 4 with 6 parallels were investigated. All of the batches 
had to follow the criteria for upper and lower limits of detection 
and to follow linearity.
Precision
To find out the maximal variation due to technicians and micro-
scopic analysts, two technicians performed the positive and negative 
control tests (each technician performed one 48-well plate of nega-
tive control and one 48-well plate of positive control). The negative 
control was tested in the angiogenesis assay with endothelial basal 
medium (EBM) without any growth factors. The positive control 
was tested in the angiogenesis assay with one VEGF and FGF-2 
dilution, i.e., positive control (10 ng/ml VEGF and 1 ng/ml FGF-2). 
Total variation in the test had to be ≤15% analyzed with CV. It is 
known, that cell culture conditions may be affected by the position 
of the well in the plate. Therefore, the whole plate was used to test 
the maximal variation including technicians, microscopic analysts, 
and cell culture conditions within plate.
Reliability
To test the reliability, two technicians repeated the test three times 
in unchanged conditions for all the reference chemicals. Reliability 
included repeatability, i.e., the positive control and the reference 
chemicals must give comparable results regardless of the testing 
time, and reproducibility, i.e., the effect of each reference chemical 
must be the same regardless of the technician. The positive control 
included altogether 24 parallels performed at three consecutive days 
by two technicians and each testing time included four parallels. 
The positive control contained four parallels and was always placed 
at the same position in a 48-well plate.
Repeatability. The test was performed by two technicians – micro-
scopic analyst – pairs three times using identical protocol (day to 
day variation).
Reproducibility. Two technician – microscopic analyst – pairs 
repeated the same identical test protocol (person to person 
  variation). In addition, each analyst analyzed all plates.
analysts with paired t-test. All statistical analyses were performed 
using GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla,   
CA, USA).
test accePtance crIterIa
Technical criteria
Three wells of the positive control had to give values 6–7 at each 
testing time. One well could give value 5. Then, the calculated 
minimum value for positive control is 5.75. The negative control 
had to be always negative (0). Only one out of two parallels in one 
combination of each reference chemical during each testing time 
could be discarded based on visual inspection in case the cells were 
found to be dead or detached.
Sensitivity of detection
For sensitivity of detection, linearity as well as upper and lower 
limits of detection, were investigated. Eight different growth fac-
tor cocktail concentrations (VEGF and FGF-2, 10:1) were used 
(Table 1) and investigated in order to find the optimal cocktail for 
positive control.
Linearity. Linearity was tested in order to find out the growth factor 
cocktail concentration range that induces tubule formation in a 
linear manner. For linearity testing, the negative control, and dif-
ferent growth factor cocktails (VEGF and FGF-2, 10:1) were used 
(see Table 1). Each cocktail was tested in six parallels.
Upper and lower limits of detection. The dose–response effect of 
the growth factor cocktails were investigated, and the combination 
of growth factors (see Table 1 for the growth factor cocktails used) 
giving the maximum value in the linear part of the response curve 
was selected to be the upper limit of detection. This was also chosen 
as the fixed positive control for the test (see Positive and Negative 
Controls). For the lower limit of detection, the growth factor cock-
tail that gives value 1 in the linear range of the tubule formation 
scale was selected. Each cocktail was tested in six parallels.
Batch to batch variation
Testing of the batch to batch variation between different HUVEC 
batches (different umbilical cords, i.e., donor samples) was per-
formed to confirm that each of the Master cell bank batches set 
FiGuRE 1 | Angiogenesis in vitro assay. The BJ fibroblast HUVEC co-culture 
was immunostained with anti-vWf antibody (1:5000) and with DAB Substrate 
kit. (A) Negative control, no tubule development (value 0 in tubule formation 
grading). Endothelial cells remain as epithelial-like round areas in co-culture. 
(B) Positive control (cocktail of 10 ng/ml VEGF and 1 ng/ml FGF-2) inducing tubule 
network formation (value 7 in tubule formation grading). Cells form tubule-like 
structures connecting to each other. Extensive branching of cells and long 
structures that cover the whole area of the well. Scale bar 500 μM.Frontiers in Pharmacology  | Predictive Toxicity    January 2011  | Volume 1  | Article 147  |  6
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the tubule formation remained quite constant and high. During 
cultivation, when the passage number increased, the tubule forma-
tion decreased. Thus, the passage 4 was chosen as the fixed passage 
to be used in the angiogenesis assay.
cytotoxIcIty test
The concentration giving the viability of 80% or higher was taken 
as the highest concentration to be used in the angiogenesis assay. 
Consequently, the concentration ranges were as follows: levamisole 
0.01–2000 μM, thalidomide 10–500 μM, erlotinib 0.0005–50 μM, 
2-ME 0.01–2 μM, and anti-VEGF 0.5–50 μg/ml. Only ASA showed 
toxicity. The toxicity was found at 2000 μM. Therefore the concentra-
tion range for ASA used in angiogenesis assay was 10–1500 μM.
angIogenesIs assay
Technical validity of the test
Positive control in each testing time gave the values 6–7 from 3 
out of 4 parallels. Negative control always gave 0. No wells needed 
to be discarded.
Intra-laboratory pre-validation parameters
Sensitivity of detection. The sensitivity of detection was evaluated 
by studying linearity and the upper and lower limits of detection. 
Figure 3A shows the results obtained with HUVEC in the angiogen-
esis assay (three batches). The response was linear up to the growth 
factor cocktail of 10 ng/ml VEGF and 1 ng/ml FGF-2 with all three 
batches. At cocktails with higher growth factor concentrations, the 
response decreased. The growth factor cocktail that caused maxi-
mal tubule formation in the linear part of the response curve was a 
combination of 10 ng/ml VEGF and 1 ng/ml FGF-2 (Figure 3B) and 
was the upper limit of detection. This combination was also chosen 
as the fixed positive control for the test (see Positive and Negative 
Controls). The lowest VEGF and FGF-2 cocktail combination that 
induced tubule formation (value 1 in microscopic analysis of tubule 
formation grading) was found to be a combination of 1 ng/ml VEGF 
and 0.1 ng/ml FGF-2. This was the lower limit of detection.
Batch to batch variation. The batch to batch variation was tested 
between three HUVEC batches treated with positive control (each 
batch with six parallels). The results are shown in Table 3. It was 
Performance
The overall performance of the assay was tested by repeating the 
identical protocol with six different reference chemicals three times 
by two technician – microscopic analyst – pairs.
test Method data qualIty
All work was performed according to the Good Laboratory Practice 
Regulations as set forth in OECD [ENV/MC/CHEM (98)17], in 
accordance with OECD guidelines [OECD Guidance document on 
the Validation and international Acceptance of New or Updated Test 
Methods for Hazard Assessment (OECD, 2005, No 34) and CPMP/
ICH/281/95] and ECVAM (European Centre for the Validation of 
Alternative Methods) guidance documents (http://ecvam.jrc.it/) and 
according to the standard operating procedures of FICAM.
results
PrIMary huvec Master cell bank oPtIMIzatIon
The tubule formation potency of HUVEC (treated with the positive 
control) was studied up to passage 10. The results of the passage 
optimization are seen in Figure 2. It was seen that up to passage 4 
FiGuRE 2 | Tubule formation potency of the positive control in the 
angiogenesis assay at different HuVEC passages. The results are given as 
mean ± SD. The results are averages of at least three separate experiments.
FiGuRE 3 | (A) Upper and lower limits of detection of tubule formation for three different HUVEC batches (HUVEC-12, HUVEC-15, HUVEC-16, n = 12 in each 
curve; (B) the linearity of tubule formation as tested from three different HUVEC batches with linear regression (n = 36). The growth factor concentrations are 
shown as VEGF concentrations. The concentrations of VEGF and FGF-2 used are seen in detail in Table 2. VEGF/FGF-2 ratio was always 10:1. The results are given 
as mean ± SD.www.frontiersin.org  January 2011  | Volume 1  | Article 147  |  7
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when the results of technician 1 were analyzed and 2.37%, when 
the results of technician 2 were analyzed. No statistically significant 
difference (p = 0.2084) was observed between the analysts. When 
comparing the technicians to each other (person to person varia-
tion), a statistically significant difference was observed (p = 0.007), 
whereas no person to person variation between analysts was seen 
However, the total CV, i.e., the total variation in the assay was as 
low as CV = 1.39%.
Performance
The performance of the assay was assessed by six different refer-
ence chemicals with several concentrations of each. The results of 
the effects of reference chemicals on tubule formation are seen in 
Figure 4. All the reference chemicals inhibited tubule formation as 
expected. Although the response was reference chemical specific, 
the phenomenon was repeatable, and variation remained constant 
throughout the study. The tubule inhibition was calculated to be 
mild (20% inhibition from positive control), moderate (40–60% 
inhibition from positive control or strong (75–85% inhibition 
from control). The severity of inhibition and the concentrations 
causing mild, moderate, or strong inhibition are summarized in 
Table 6, where the reference chemical results of our in vitro assay 
are compared to other in vitro angiogenesis test methods, to the 
relevant plasma concentrations in clinical studies and to effective 
doses from animal studies.
dIscussIon
The present intra-laboratory pre-validation study showed that 
a standardized in vitro angiogenesis assay is reliable and repro-
ducible for testing the modulators of angiogenesis, and this 
human primary cell based in vitro assay mimics well the effects 
in man. Thus, it has great potency to supplement and/or replace 
animal tests.
Appropriately pre-validated human cell in vitro assays are 
urgently needed for reducing and replacing animal tests. In vitro 
angiogenesis assays are regarded as useful tools for screening com-
pounds and their effective concentrations, but due to complex 
interactions during angiogenesis, they often need to be followed 
by in vivo studies (Auerbach et al., 2003). Animal assays, although 
not necessarily predictive for effects in human, are widely used 
as they provide information on complex cellular and molecular 
interactions (Norrby, 2006). The disadvantages of the current in 
vitro assays are that they lack metabolism and are rarely completely 
based on human biology (Auerbach et al., 2003).
seen, that the criteria for positive control value were met with all 
batches and that the variation between the batches was extremely 
small (CV = 1.72%).
Precision. To find out the maximal variation, including that caused 
by technicians and microscopic analysts, the angiogenesis assay 
with positive and negative controls was performed. The results 
of the positive and negative control and their CV% are shown 
in Table 4. Negative control was always found to give the value 0 
however; the CV% of positive control was found to be between 
6.27 and 7.82%.
Reliability
Repeatability. The results of day to day variation between techni-
cians and microscopic analysts are presented in Table 5. No sig-
nificant differences were observed among technicians (p = 0.906 
and p = 0.064). The microscopic analyst–technician pairs had 
following day to day variation: microscopic analyst 1 technician 
1 CV = 0.59%, microscopic analyst 2 technician 1 CV = 0.67%, 
microscopic analyst 1 technician 2 CV = 6.38%. Microscopic ana-
lyst 2 technician 2 CV = 5.02%. We further studied whether the 
variation was due to analysis or due to technical performance (see 
Reproducibility).
Reproducibility. When the person to person variation was studied, 
each analyst analyzed all plates. Overall there was only a minor 
difference in CV% between technicians [the results of technician 
1 or technician 2 were analyzed by both (two) analysts], being 
0.64% with technician 1 and 5.63% with technician 2. The person 
to person variation is seen in Table 5. The results showed that the 
CV% between microscopic analysts was very low; CV% was 0.34% 
Table 3 | Batch to batch variation in tubule formation between three 
HuVEC batches (HuVEC-12, HuVEC-15, HuVEC-16, n = 12 with each 
batch).
  Criteria  HuVEC-12  HuVEC-15  HuVEC-16
Positive control  ≥5.75  7 .417  7 .500  7 .250 
(mean)
Mean (three  ≥5.75   7 .389 
batches)
Variation (CV%)  ≤15%   1.72%
CV%, coefficient of variation (%).
Table 4 | The precision of the in vitro angiogenesis assay. Maximal variation in the angiogenesis assay was tested with positive and negative controls (Two 
pairs of microscopic analyst–technician performing each one 48-well plate of negative control and one 48-well plate of positive control).
  Criteria  Technician   Technician   Technician   Technician  
    1–microscopic  1–microscopic  2–microscopic  2–microscopic 
    analyst 1  analyst 2  analyst 1  analyst 2
Positive control (mean)  ≥5.75  6.354  6.771  6.896  6.958
Negative control   0  0  0  0  0
Variation (CV%)  ≤15  7 .61  6.27  6.85  7 .82
CV%, coefficient of variation (%).Frontiers in Pharmacology  | Predictive Toxicity    January 2011  | Volume 1  | Article 147  |  8
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The optimal positive control concentration, i.e., VEGF/FGF-2 
growth factor cocktail was obtained by investigating the biologi-
cal response of several growth factor concentrations in several 
HUVEC batches. The positive control optimization resulted in 
stable and repeatable effect. The batch to batch variation for 
HUVEC was minimal due to the optimized passage and pre-set 
QC criteria for the cells stored in Master cell bank. Moreover, 
the test duration was shortened from previous methods (Bishop 
et al., 1999; Donovan et al., 2001) from 14 to 6 days of co-culture 
and the assay setup was optimized for 48-well plate to minimize 
the use of cells and to increase the capacity. A semi-quantitative 
microscopic analysis method, based on tubule formation, their 
connections and the complexity of the developed network, was 
developed. The prerequisite for the semi-quantitative grading 
was that the analysis covered the whole area of each well, con-
trary to the method of Bishop et al. (1999), where images taken 
from only five random fields in larger wells (24-well plates) were 
analyzed by computer analysis program. In optimization phase, 
the performance assay was tested with 19 reference chemicals; 
We further developed, optimized and finally intra-laboratory 
pre-validated the previously published angiogenesis assay (Bishop 
et al., 1999). Our assay is based on quality-controlled primary 
HUVEC that have been minimally expanded in vitro. The optimi-
zation of the HUVEC passage number was found to be one crucial 
factor for the adequate performance of the assay. The tubule forma-
tion ability decreased significantly after serial passaging. Based on 
the optimization phase, the use of one, fixed passage of HUVEC 
was found to be optimal. This shows, that the effect of passage 
number on the biological activity of cells has to be investigated and 
the passage number fixed in order to maintain repeatability of the 
assay. Through optimization, we could obtain a routine assay with 
minimal variation (overall CV% between the two technicians and 
microscopic analysts was 1.39%). However, statistically significant 
difference was found between technicians. The effect of this on the 
final results is avoided by using positive and negative controls as 
there was no significant difference in day to day variation among 
technicians. They are used to calculate the response of unknown 
substances, as well as used as internal controls in the assay.
Table 5 | Day to day variation (repeatability) and person to person variation (reproducibility) between the technicians and the microscopic analysts. 
Criteria set and the positive control values obtained.
Reproducibility and repeatability
  Criteria set for  Obtained positive control value 
  positive control/ 
  CV%/p-value
    Technician  Technician  Technician  Technician 
    1 –microscopic  1 – microscopic  2 –microscopic  2 –microscopic 
    analyst 1   analyst 2   analyst 1  analyst 2 
    mean (n = 24)  mean (n = 24)  mean (n = 24)  mean (n = 24)
Day 1 (n = 48)  ≥5.75  5.79  5.833  5.75  5.75
Day 2 (n = 48)  ≥5.75  5.833  5.833  6.583  6.083
Day 3 (n = 48)  ≥5.75  5.875  5.75  6.625  6.5
Mean between days   ≥5.75  5.833  5.805  6.319  6.111
Day to day variation among   ≤15%  0.59%  0.67%  6.38%  5.02% 
technicians (CV%)
Day to day variation among  p < 0.05    ns, p = 0.906     ns, p = 0.064 
technicians (one-way ANOVA)
Day to day variation between   ≤15%    0.34%      2.37% 
analysts (CV%)
Person to person variation     0.64%      5.63% 
between technicians
Person to person variation  p < 0.05       p = 0.007 
between technicians (statistical  
significance, unpaired t-test)
Person to person variation  p < 0.05       ns, p = 0.2084 
between analysts (statistical  
significance, paired t-test)
Total mean of positive control  ≥5.75       6.017
Total variation of positive   ≤15%       1.39% 
control (CV%)
CV, coefficient of variation, ns, non-significant.www.frontiersin.org  January 2011  | Volume 1  | Article 147  |  9
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used (Donovan et al., 2001; Auerbach et al., 2003). However, 
compared to several previous in vitro studies, our assay shows 
improvement of sensitivity.
The relevance of the assay to man was investigated by compar-
ing the obtained reference chemical results with data from clinical 
studies. The effective concentrations observed in our assay showed 
very good concordance with the respective therapeutic plasma con-
centrations (Table 6). The plasma concentrations of anti-VEGF 
obtained from different clinical trials varied extensively. One expla-
nation is that the endogenous plasma concentrations of VEGF and 
FGF-2 differ among individuals and are also dependent on the 
disease (Kakimoto et al., 2002).
In conclusion, we here show that through thorough optimiza-
tion, it is possible to develop a cell culture assay into a reproducible 
and repeatable routine method with minimal variation and with 
easy and fast semi-quantitative quantification of the end points. 
The intra-laboratory pre-validation study was completed success-
fully, the test was technically accepted and the pre-set acceptance 
criteria were met. In comparison of the results to the data from 
clinical trials shows that this human cell based in vitro angio-
genesis assay mimics very well the effects in man, and thus it can 
be used to replace and/or supplement animal tests when testing 
angiogenesis modulators. The applicability domain contains so far 
pharmaceuticals. In addition to the chemical testing, the method 
has potency to test conditioned media of cells or even the effect of 
different cells (normal or cancer cells) with regard to their effect 
on angiogenesis.
endostatin, interleukin-1 soluble receptor 1 (IL-1 SR1), suramin, 
mevinolin, paclitaxel, fumagillin, anti-epidermal growth fac-
tor receptor (anti-EGFR) cyclooxygenase-2-specific inhibitor 
NS-398, indomethacin, VEGF, anti-VEGF, FGF-2, anti-FGF-2, 
platelet-derived growth factor beta (PDGF-BB), levamisole, erlo-
tinib, ASA, 2-ME, and thalidomide.
The performance of the in vitro angiogenesis assay was proven 
in intra-laboratory pre-validation with six different reference 
chemicals (levamisole, ASA, thalidomide, erlotinib, anti-VEGF, 
and 2-ME). The obtained results were compared to the pub-
lished data from other in vitro angiogenesis assays (Table 6). 
The table shows that comparable results were detected with 
ASA (Borthwick et al., 2006), with erlotinib (Birle and Hedley, 
2006; Jimeno et al., 2007), and with 2-ME (Dobos et al., 2004). 
However, 2-ME had previously shown low inhibition at 10 μM 
and moderate inhibition at 50 μM (Kang et al., 2006), whereas 
our assay showed low and moderate inhibition at 0.01–0.2 and 
1 μM, respectively. Moreover, compared to the method by Friis 
et al. (2003, 2005), which is a similar assay to ours, levamisole 
was reported to have mild inhibition at 500 μM (in our study 
0.01–1 μM), moderate at 750–1000 μM (in our study 100–
500 μM), and strong at 2000 μM (in our study 1000–2000 μM). 
The anti-VEGF was reported to have moderate to strong inhibi-
tion at 0.1–10 mg/ml in an in vitro model with different study 
setup (Sims et al., 2008) compared to our assay (inhibition at 
0.5–50 μg/ml). There are known to be marked differences in 
tubule formation depending on the in vitro angiogenesis assay 
FiGuRE 4 | The performance of the assay. The effects of the reference 
chemicals on tubule formation. The results are given as mean ± SD, n = 24 
including three testing times with two technicians. Microscopic analysis of all 
wells was performed individually by two analysts. The results were tested 
statistically by using one-way ANOVA with Dunnett’s post test. *p < 0.05, 
**p < 0.01 and ***p < 0.001.Frontiers in Pharmacology  | Predictive Toxicity    January 2011  | Volume 1  | Article 147  |  10
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Table 6 | The comparison of the results from intra-laboratory pre-validated  assay to the results from other in vitro methods, clinical studies and 
animal models.
Mild inhibition 
(% of control) 
<20%
Moderate 
inhibition (% of 
control) 40–60%
Strong 
inhibition (% of 
control) 75–85%
inhibitory effect and 
concentration
Cmax Effective dose (ED)
Acetyl salicylic acid 1.8–8 μg/ml 
(10–100 μM)
180 μg/ml 
(1000 μM)
270 μg/ml 
(1500 μM)
Moderate 500 μM 
(Borthwick et al., 
2006)
• 260–1026 μM (Juárez 
Olguín et al., 2004)
•   26–300 μM, CAM 
model (Sharma 
et al., 2001)
• 0–25 μg/ml (Maalouf 
et al., 2009)
• 170 ± 96.7 ng/ml (Bae 
et al., 2008)
Erlotinib (EGF 
receptor tyrosine 
kinase inhibitor)
0.04–40 ng/ml 
(0.5 nM–
0.1 μM)
4 μg/ml (10 μM) 22 μg/ml (50 μM) Mild 1–20 μM (Birle 
and Hedley, 2006), 
Moderate 10 μM 
(Jimeno et al., 2007)
• 0.3–1.13 μg/ml 
(Herbst et al., 2005)
• 0.251–10.7 μg/ml 
(Ranson et al., 2010a)
• 2.93 ± 1.3 μg/ml 
(Ranson et al., 2010b)
• 0.3 μM (Clarke et al., 
2010)
• 0.56–4 μM (Kraut 
et al., 2010)
•   50 mg/kg, Mouse 
carcinoma model 
(Jimeno et al., 2007)
•   50 mg/kg, Mouse 
tumor model 
(Cerniglia et al., 
2009)
Levamisole 2–240 ng/ml 
(0.01–1 μM)
25–120 μg/ml 
(100–500 μM)
240–500 μg/ml 
(1000–2000 μM)
Mild 500 μM, 
moderate 750–
1000 μM, strong 
2000 μM (Friis et al., 
2005), strong 
2000 μM (Sylvest 
et al., 2010)
• 0.62 μg/ml–1.27 μg/ml 
(Reid et al., 1998)
• 0.716 ± 0.217 μg/ml 
(Kouassi et al., 1986)
•   1.2–12 mg/kg, Nude 
mouse tumor model 
(Friis et al., 2005)
•   Cmax 0.37 μg/ml calf 
parasite infection 
(Taylor et al., 1988
2-Methoxyestradiol 3–60 ng/ml 
(0.01–0.2 μM) 
300 ng/ml (1 μM) 600 ng/ml (2 μM) Mild 10 μM, moderate 
50 μM (Kang et al., 
2006), Mild 0.5 μM, 
moderate 1 μM 
(Dobos et al., 2004)
• 3.3 ng/ml (Tevaarwerk 
et al., 2009)
• 30.27 ± 20.18 ng/ml 
(Matei et al., 2009)
• 3.0–21.4 ng/ml (Dahut 
et al., 2006)
• 1.4–13.2 ng/ml 
(James et al., 2007)
• 2.2–9.6 ng/ml 
(Sweeney et al., 
2005)
•   100 mg/kg Murine 
rheumatoid arthritis 
model (Plum et al., 
2009)
•   7. 5  mg/kg, 75 mg/kg 
Mouse tumor model 
(Dobos et al., 2004)
Thalidomide 2–25 μg/ml 
(10–100 μM)
77–100 μg/ml 
(300–400 μM)
- - • 2 μg/ml (Kakimoto 
et al., 2002)
• 1.68 ± 0.41 μg/ml 
(Murakami et al., 
2009)
• 1.44 ± 0.50 μg/ml 
(Kamikawa et al., 
2006)
• 0.43–1.03 μg/ml 
(Vieira and Valente 
Mdo, 2009)
•   100 mg/kg, Rat 
Alzheimer model 
(Ryu and McLarnon, 
2008)
•   19–1000 μM, CAM 
model (Sharma 
et al., 2001)
Reference 
chemical
Results from intra-laboratory pre-validated  
angiogenesis test method
Results using other  
in vitro angiogenesis 
test methods 
Results from clinical 
trials
Results using 
animal models
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